| abstract |
Featured herein are engineered human cells, which express an exogenous extracellular binding partner to an apoptotic or necrotic cellular antigen and at least one exogenous intracellular signaling domain. These genetically-engineered cells can function as immune modulators that specifically recognize dying cells or tissues and upon binding, secrete Th1 cytokines including IL-2 and IFN-gamma, thereby achieving a localized pro-inflammatory response at the site of tumor tissues. |